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Background: This objective of the review and analysis is to demonstrate that acyclovir (ACV) 3% ophthalmic
ointment is superior to idoxuridine (IDU) in treating herpetic keratitis (HK) presenting as dendritic and geographic
ulcer sub-types.
Methods: Data sources: Publications in human subjects were identified by searching the Ovid MEDLINE database
through April 2011, combining medical subject headings (MESH) “Keratitis, Herpetic/” AND “Acyclovir/” limiting by
the key words “topical” OR “ointment” and also restricted to MESH “Administration, Topical/” OR “Ointments/”. The
results were cross checked with the references used in the Cochrane Database Syst Rev. 1:1–134, 2009 and
GlaxoSmithKline clinical documents related to acyclovir.
Study selection: Randomized, double-masked studies in subjects diagnosed with HK with head to head comparator
arms of ACV ophthalmic ointment and topical IDU that had actual or calculable healing rates at Day seven.
Data extraction: Data independently extracted from identified articles by two authors of this manuscript.
Data synthesis: Data from seven randomized, controlled trials (RCT) evaluating 432 subjects that met inclusion criteria
(214 were treated with ACV and 218 were treated with IDU) and had Day seven healing rates calculable. All sub-classified
lesions were identified as either dendritic ulcers (n = 185) or geographic ulcers (n = 35). The Cochran-Mantel-Haenszel
(CMH) method in Biometrics 10:417-51, 1954 and JNCI 22:719-48, 1959, controlling for study, was performed as the
primary analysis using SAS v9.
Homogeneity was assessed using Breslow-Day-Tarone (BDT) test in IARC 1:1-32, 1980 and Biometrika 72:91-5, 1985.
The analysis was performed with outliers removed to assess their impact.
Results: ACV showed statistically significant greater odds of healing HK at Day seven in all subjects (Odds Ratio
3.95, 95% CI2.60, 6.00, p <0.0001), in dendritic ulcers (Odds Ratio 4.22, 95% CI: 2.14, 8.32; p < 0.0001) and
geographic ulcers (Odds Ratio 5.31, 95% CI: 1.09, 25.93; p =0.0244).
Conclusion: ACV 3% ophthalmic ointment is a valuable intervention for dendritic and geographic corneal ulcers.
ACV and IDU were generally well tolerated in the studies reviewed.
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Herpetic keratitis (HK) is a well described and poten-
tially serious corneal disease. It is estimated that up to
ten million people globally have been afflicted with HK,
and the incidence of herpetic keratitis due to herpes
simplex virus is estimated to be roughly 30 per 100,000
people per year. [1] Cases of herpetic lesions of the
cornea are a longstanding source of visual disability and
have been reported in the medical literature for well
over 100 years [1,2]. The main forms of HK lesions are
(a) dendritic and geographic ulceration (often referred to
collectively as epithelial HK or superficial HK) and (b)
stromal keratitis. Epithelial HK usually presents with
thin dendritic branching ulcers, thought due to linear
spread of the virus to adjacent cells [3]. While dendritic
epithelial keratitis is the more common configuration of
epithelial keratitis, a macro-ulceration secondary to epi-
thelial infection is also seen and referred to as geo-
graphic epithelial keratitis [1]. Stromal keratitis occurs
less frequently than the epithelial manifestation, but it
often resolves more slowly [4,5]. Morphologically the
corneal stroma becomes inflamed while the epithelial
surface remains intact. Herpetic Keratitis can be a self-
limited condition and resolve without sequalae; however,
untreated, such benign cases occur in a minority of out-
comes [6]. Mechanical and nonspecific therapies such as
debridement and chemical curettage were in use prior to
the 1960’s to improve outcomes. Despite these interven-
tions signs of active HK were observed on the cornea for
an average of 21 days, and HK remained one of the most
important corneal diseases leading to loss of vision [6].
In 1962 Kaufman et al. [6] showed in an uncontrolled
trial effectiveness of topical 5-iodo-2′-deoxyuridine—(la-
ter called idoxuridine) in treating HK. Over the ensuing
two years multiple authors reported on the efficacy of
idoxuridine, including five controlled trials. Success,
often defined as the resolution of staining, was reported
in 50% to 90% of cases, and the time frame for the effi-
cacy assessment was seven days for three of the five
controlled trials [6-10]. Success rates for idoxuridine
ophthalmic ointment (IDU) generally fall in to the 75%
rate based on review of these early studies. In 1962 IDU
became the first antiviral agent approved for use in hu-
man disease [1]. Since that time newer agents have been
developed. Specifically, acyclovir (ACV) 3% ophthalmic
ointment was approved in 1981 in the United Kingdom.
With prompt attention visual outcomes in patients with
HK can be excellent [11]. Currently, ACV is utilized for
the treatment of HK as ZOVIRAX ophthalmic ointment
in the EU and many additional countries [12]. While
ACV is not approved in the United States, IDU is ap-
proved in the United States for the treatment of keratitis
caused by the virus of herpes simplex [13]. Both medica-
tions are topically applied and have similar adversereaction profiles. Ocular irritation including burning and
stinging are commonly seen immediately following ap-
plication, and a drug-induced superficial punctate kera-
topathy including corneal epithelial staining can be
observed on examination in a minority of patients using
these medicines. Interestingly, however, the efficacy pro-
files for these two medications are somewhat dissimilar.
Multiple independent studies have demonstrated that
ACV 3% ophthalmic ointment has healing rates superior
to IDU for the treatment of this condition [1,14,15]. A
meta-analysis of the efficacy between ACV and IDU
should address which drug is the more effective therapy
in HK. To compare ACV to IDU in healing HK we
reviewed well controlled, randomized trials (RCT) that
assessed the efficacy of these antivirals through healing
on Day seven of treatment in subjects with HK.
Methods
Methods of analysis and inclusion criteria were pre-
specified and documented in a protocol. These followed
the PRISMA guidelines [16].
Study selection criteria for the meta-analysis were ran-
domized, double-masked clinical trials in subjects with HK
with head to head comparator arms of ACV ophthalmic
ointment and topical IDU that had actual or calculable
healing rates at Day seven. No language, publication date,
or publication status restrictions were imposed.
No restrictions on subjects were imposed. Where pos-
sible, subjects were identified as having either dendritic
or geographic ulcers.
The Ovid search engine for the Ovid MEDLINE
database through April 2011, combining medical sub-
ject headings (MESH) “Keratitis, Herpetic/” AND
“Acyclovir/” was used to identify publications that
were then further limited by the key words “topical”
OR “ointment”. Separately, the initial results generated
by combining (MESH) “Keratitis, Herpetic/” AND
“Acyclovir/” were also restricted to MESH “Adminis-
tration, Topical/” OR “Ointments/”. All papers were
limited to those concerning human subjects.
All unique papers identified above were cross checked
with the references utilized in major reviews including
the 2009 Cochrane report [1] and in GlaxoSmithKline
clinical development documents related to acyclovir.
The resulting studies were reviewed by the team mem-
bers against selection criteria, and disagreements were
resolved by consensus of the team.
Day seven healing rates were extracted independently
by two team members (MAF and GQ) and cross
checked. When interpreting the publications/reports the
following two terms were used interchangeably: “superfi-
cial herpetic keratitis” and “epithelial herpetic keratitis”.
Additionally, the meta-analysis did not include subjects
that were excluded in the final analysis by the publication.
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seven healing or cure. In that case, values were based on
tables and figures in the articles.
When a subject did not provide data on Day seven of
treatment the following rules were applied:
 If the subject provided data showing the disease
status before the completion of Day seven, the same
disease status was used as his/her disease status for
Day seven of treatment;
 If the subject did not provide any data before Day
seven, but provided data showing disease status after
that, failure of cure was carried forward for the
subject at Day seven;
 If the subject was enrolled but did not provide any
data on disease status, the subject was excluded
from meta-analysis.
Risk of bias of individual studies was low due to selec-
tion of RCTs.
The meta-analysis was performed in a sequential man-
ner to control the overall type I error rate at 5%: data
from subjects with HK were analyzed first; the analysis
of data from subjects with dendritic and geographic ul-
cers was further performed at the 2.5% level to maintain
the overall type I error rate at 5% level. Superiority was
defined as statistically significant higher response rate.
To compare the efficacy of ACV to IDU, the
Cochran-Mantel-Haenszel (CMH) method [17,18], con-
trolling for study, was performed as the primary ana-
lysis. Point estimates and the corresponding 95%
confidence intervals (CIs) of the estimated common
odds ratio across studies were provided together with
the CMH test statistics and p-value for each ulcer type.
To estimate the efficacy of ACV and of IDU, the non-
linear mixed effect (NLME) model (logistic regression
model, based on maximum likelihood method) fitting
treatment as a fixed effect and study as a random effect,
was performed. Point estimates and the corresponding
95% CIs for the log odds of Day seven healing rate for
both products were derived. The log odds and the corre-
sponding 95% CIs were then back calculated to the scale
of odds and healing rate for each treatment.
Homogeneity was assessed using Breslow-Day-Tarone
(BDT) test [19,20] based on the odds ratio (OR). The
publications deemed as statistical outliers were removed
and the analysis was re-conducted to check the potential
impact of the outlier on the result.
To summarize the data available, the determination of
Day seven healing rates for ACV and IDU was calculated
by combining the number of subjects healed over the se-
lected studies, and dividing by the total number of cor-
responding subjects treated with that antiviral over the
selected studies. The 95% CIs for the healing rates foreach treatment group were also calculated using a nor-
mal approximation. All analyses were performed with
SAS v9.
Safety data from the publications in the meta-analysis
was reviewed and summarized. No formal analysis of
safety was performed.Results and discussion
Publication review
The flow of information through the systematic review
is displayed in Figure 1.
Using the Ovid MEDLINE database through April 2011,
combining MESH “Keratitis, Herpetic/” AND “Acyclovir/”
resulted in 400 peer reviewed publications. Limiting these
by the key words “topical” OR “ointment” resulted in 150
articles. Of these, 125 pertained to human subjects. Simi-
larly, when the 400 articles were restricted to MESH “Ad-
ministration, Topical/” OR “Ointments/”, 80 articles
remained. Limiting these 80 papers to human subjects
yielded 67 papers. The total number of unique papers be-
tween these sets yielded 132.
Attention was then placed on selected review articles
including the 2009 Cochrane report [1] and GSK docu-
ments. The reference list from these documents was
cross referenced with the above set of 132 papers to
identify 47 additional articles discussing the clinical use
of ACV ophthalmic ointment that were not captured in
the primary literature search. The total number of peer
reviewed publications reporting on the clinical use of
ACV ophthalmic ointment was 179.
Searching GSK archives located a further 13 clinical
reports.
Randomized, double-masked studies in subjects with
HK with head to head comparator arms of ACV 3%
ophthalmic ointment and topical IDU were then selected
from the 179 publications and from the 13 GSK clinical
reports. Those that had actual or calculable healing rates
at Day seven were used for the primary efficacy ana-
lysis. Ultimately, 6 publications and 1 unpublished GSK
summary report (Table 1) were identified for the meta-
analysis to support primary efficacy. Four of the published
study reports had corresponding GSK documentation.
When these publications were compared to the GSK re-
ports, safety and efficacy information was consistent and
complete between the two different reports of the same
clinical trial, and therefore the publication was used as the
source for this meta-analysis.
Publications that were used are Colin [21]; Collum [22];
Coster [23]; Kitano [24]; Klauber [25]; and McCulley [26].
The unpublished GSK summary report will be referred
to as Hamard [27]. Relevant data is reproduced in Figure 2.
Following the completion of this review, the 2010 up-
date to the Cochrane Review [28] was published. It was
Figure 1 The flow of information through the systematic review.
Table 1 Definition of endpoints and cure/healing of the publications/report identified by systematic review
Article Definition
Colin [21] Endpoints: Number of cures during treatment period, mean time to cure.
Definition of cure: the absence of epithelial ulceration after instillation of fluorescein
using biomicroscopic examination.
Collum [22] Endpoints: Days to heal and total number of subjects healed.
Definition of healing: Ulcers were considered to have healed when there was no fluorescein uptake. Ulcers that
did not show improvement by day 4 were treated with ara-A ophthalmic ointment and withdrawn.
Coster [23] Endpoints: Treatment failures, number of days it took ulcers to heal.
Definition of healing: no epithelial defect demonstrable with Rose Bengal and fluorescein staining
Hamard [27] GSK Report Endpoints: cumulative cure rate, average healing time.
Definition of healing: Resolution of the ulcer based on fluorescein staining (inferred).
Kitano [24] Endpoints: comparing treatment efficacy between study groups.
Definition of healing: Based on ulcer appearance over time; reported by categories, as follows: Excellent (ulcer
disappeared within 7 days), Good (ulcer disappeared within 14 days or reduced by 50% within 7 days), Fair
(ulcer reduced by 50% within 14 days), None (ulcers not reduced by 50% within 14 days).
Klauber [25] Endpoints: Cumulative healing rates.
Definition of cure: The keratitis was judged to have been cured, at the time when there were no demonstrable
epithelial defects by fluorescein and Rose Bengal and with the disappearance of the stromal affection and injection
McCulley [26] Endpoints: Corneal epithelial healing is the primary measurement of efficacy.
Definition of healing: the observation of the absence of fluorescent staining and/or faint, segmented staining
(“ghost figures”) in the area of previous corneal ulceration within the therapy period without recrudescence.
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Figure 2 Hamard [27] Day Seven healing rate graph.
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mation included for acyclovir; none were determined to
have an impact on the outcome of the original search or
the meta-analysis plan or results, or any conclusion
based on information from the 2009 document [1]. Fur-
thermore, none of the selected studies included subjects
without epithelial disease, thus healing rates for stromal
keratitis were not evaluated in this meta-analysis. The
total number of subjects was 432, with 214 receiving
ACV and 218 receiving IDU. Regarding dosing, it was
generally consistent across the studies with each drug
being used five times per day through lesion resolution
or 14 days.Efficacy data
Seven-day healing rates, defined as proportion of study sub-
jects healed at seven days after study entry, were chosen as
the primary outcome measure for this analysis. The choice
of Day 7 was influenced by the natural history of the dis-
ease, its use as a time point in head to head clinical trials,
and the fact that resolution of HK in seven days is a favor-
able outcome and a reasonable therapeutic goal [1]. In fur-
ther support of Day 7 as the key endpoint for this meta-
analysis untreated HK can take up to three weeks to resolve
making resolution within a week a therapeutic success, and
many of the original idoxuridine studies utilized a day seven
endpoint in their analyses [6,10]. Table 1 is the summary of
definition of endpoints and healing from the publications
identified by the systematic review.
Table 2 Summary of healing rate for HK, dendritic and
geographic ulcers at Day 7 reports the detailed day 7
healing rates for each individual report.In keeping with many clinical trials assessing therapy
for HK, the diagnosis in these studies was based on the
clinical appearance of the cornea. Although it may ap-
pear optimal to only analyze cases in which the presence
of herpes simplex was confirmed by culture or alterna-
tive laboratory testing, it wasn’t possible to break down
the study results based on this parameter. For example,
Coster [23], Klauber [25], and Hamard [27] used clinical
criteria only. In Colin [21], a viral sample was taken for
the majority of cases, but no culture results are reported.
Collum [22] showed recovery of herpes simplex virus
type I in 19 (33%) of 54 conjunctival swabs while com-
plement fixation antibody to HSV type I was present in
48 (96%) samples of sera. Collum [22] also reported a
case by case analysis of recovery of virus and titer of
complement fixing antibody. McCulley [26] utilized
virus cultures from the inferior cul-de-sac and showed a
19.9% positive culture rate. Kitano reported that virus
was isolated in 61.5% of cases. None of these four studies
that evaluated subjects for presence of virus separated out
their aggregate results based on confirmation of virus. Of
note, polymerase chain reaction testing was not available
at the time these studies were conducted. It was felt that
re-evaluating the Collum study, only, based on isolation of
virus from the conjunctiva was not necessary. Further-
more, routine management of HK does not require la-
boratory confirmation prior to initiating therapy, thus the
use of the broader population has clinical relevance [15].
Ulcer size is another variable that can affect responses
to antiviral therapy. Five studies provided useful infor-
mation about baseline ulcer size. Coster [23], Collum
[22], Colin [21], McCulley [26], and Hamard [27] all pre-
sented a comparison of ulcer sizes between the ACV and
Table 2 Summary of healing rate for HK, dendritic and geographic ulcers at Day 7
Study Healed/Total (%)
Herpetic keratitis Dendritic ulcers Geographic ulcers
ACV IDU ACV IDU ACV IDU
Colin [21] 19/25 (76) 11/27 (41)
Collum [22] 29/30 (97) 6/29 (21) 29/30 (97) 6/29 (21)
Coster [23] 27/29 (93) 24/30 (80) 27/28 (96) 22/26 (85) 0/1 (0) 2/4 (50)
Hamard [27] 21/28 (75) 12/23 (52)
Kitano [24] 40/54 (74) 26/55 (47)
Klauber [25] 12/18 (67) 6/20 (30) 8/10 (80) 5/10 (50) 4/8 (50) 1/10 (10)
McCulley [26] 19/30 (63) 18/34 (53) 16/26 (62) 17/26 (65) 3/4 (75) 1/8 (12)
Summary 95% 167/214 (78) 103/218 (47) 80/94 (85) 50/91 (55) 7/13 (54) 4/22 (18)
CI of summary (72%, 84%) (41%, 54%) (78%, 92%) (45%, 65%) (27%, 81%) (2%, 34%)
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based on analysis of the ulcer size between the groups.
Kitano [24] and Klauber [25] did not describe subject
ulcer size. It was not possible to reevaluate outcomes
based on presenting ulcer size, but based on the similar-
ities between study arms regarding ulcer size in the five
studies that mentioned it, such an assessment was not
necessary. Although knowing corneal drug concentra-
tion in drug development is important and would pro-
vide additional information relating to efficacy in these
cases, neither corneal nor aqueous humor drug levels
were provided in these studies [29]. Likewise, sensitivity
testing for drug resistance was not performed.
For some studies, all the healing rates were directly de-
scribed in the report. In other cases derivation was less
straight forward and is explained in detail below:
In Coster [23], the total numbers cured at Day seven
had to be extracted from the cumulative time course
plots of healing and are reported in Table 3. The num-
bers of subjects healed at different days are tabulated in
the publication. Although 30 subjects were enrolled per
arm, “One patient treated with acyclovir failed to present
regularly for follow-up, though he responded favourably
in that his geographic ulcer had healed when he returned
10 days after beginning therapy.” As this subject was not
included in the analysis in the publication, he was also
excluded from the GSK analysis.Table 3 Number of subjects healed based on Figures 2 and 3
Treatment Group Day 6 Day 7 Day
Acyclovir Herpetic keratitis 27 27 28
Dendritic ulcers 27 27 28
Geographic ulcers 0
Idoxuridine Herpetic keratitis 21 24
Dendritic ulcers 19 22 23
Geographic ulcers 2 2
Note: Bolded values were derived from other cells, unbolded cells were determinedIn Hamard [27], no corresponding publication of
these data was found. Total number of subjects cured
at Day seven were extracted based on the cumulative
frequency plot in the GSK report. Although the word
“dendritic” was used in the abstract, the enrolment
states “superficial herpetic keratitis”, and geographic ul-
ceration was not an exclusion criterion. Therefore, the
disease type in this study appears to be “epithelial” or
“superficial” keratitis generally, and not dendritic ulcer
only. No breakdown is provided based on dendritic
ulcer or geographic ulcer sub-type in this report, and
hence was excluded from the sub-type analysis. See
Table 2 for the derived outcome and Figure 2 for the
original results in the report.
In KIauber [25], the total number of subjects cured at
Day seven was extracted based on the cumulative fre-
quency plots in the publication.
In McCulley [26], the total numbers of subjects by
treatment for each ulcer sub-type were available. Based
on Figure 3 in the article, at Day seven the total number
of HK subjects cured was 19 of 30 for ACV and 18 of 34
for the IDU group.Safety data
Brief summaries of reported safety information are
provided.of [23]




26 28 30 30
25 26 26
3 4 4
directly from Figures 2 and 3 of [23].
Figure 3 Primary Meta Analysis Result with CMH Method for Herpetic Keratitis. CMH: Cochran-Mantel-Haenszel method; OR: Odds Ratio; CI Low: Lower
bound of 95% confidence interval; CI Up: Upper bound of 95% confidence interval; ACV: acyclovir; IDU: idoxuridine; Confidence limits were truncated
and presented as arrows if they were outside the range 0 to 10; (e.g. the upper confidence interval from Colin [21]). The entire confidence interval for
the estimate from Collum [22] was above 10 (with a lower CI of 12.48) and therefore only the lower limit was shown as an arrow. The point estimate
of the Odds Ratio for each study is represented by the squares, where the size of the square is proportional to the precision of the estimate. The kite
shaped quadrilateral at the bottom of the graph has left and right endpoints at the lower and upper confidence intervals respectively, and the vertices
of the kite shape that are its highest and lowest point vertically align at the point estimate of the Odds Ratio from the meta-analysis.
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(AEs) in each group. In the ACV group the AEs were
punctate keratitis, punctate keratitis with follicular con-
junctivitis, follicular conjunctivitis, and allergy of the
eyelids. The IDU group showed two cases of punctate
keratitis and two cases of follicular conjunctivitis. Toler-
ance to the two compounds was similar, and the side ef-
fect profile was also similar between the groups.
Collum [22] reported that no serious adverse events
(SAEs) were observed, although transient stinging was
recorded in eight subjects receiving ACV ophthalmic
ointment and in two subjects receiving IDU. Other
AE’s in the IDU group were watering of the eyes in two
subjects and superficial punctate erosions in six
subjects.
Coster [23] reported that there were no AEs which re-
quired withdrawal of therapy. Six ACV treated patients
and two IDU treated subjects experienced stinging. One
subject (treatment not indicated) developed an allergic
reaction that subsided on withdrawal of the atropine
drops.
Hamard [27] reported that punctate keratopathy was
the only adverse effect, seen in four cases receiving ACV
ophthalmic ointment and five receiving IDU. There were
no hematological or biochemical changes seen in any
subject in the study during the course of therapy. Both
drugs were well tolerated during this relatively short
period of exposure.
Kitano [24] reported that both treatment arms had
AEs that were similar in nature, including superficial
keratitis (12 in ACV ophthalmic ointment group, seven
in the IDU group) and two cases (one in each group) of
other external ocular irritation.
Klauber [25] reported that only minor adverse reac-
tions were recorded in both treatments.McCulley [26] reported that the only significant dif-
ference (P < 0.01) in the frequency of development of
adverse reactions was found in the incidence of devel-
opment of superficial punctate epitheliopathy (IDU, 42%;
ACV ophthalmic ointment, 11%).
Results of meta-analysis
The formal meta-analysis results comparing ACV versus
IDU are presented Table 4 and in Figure 3. The results
of healing rate estimation for ACV and IDU are pre-
sented in Table 5.
Based on the result from the meta-analysis with the
CMH method (Table 4), in subjects with HK, the odds
ratio (OR) of healing at Day 7 in the ACV treatment
group is 3.95 times (95% CI: 2.60, 6.00; p-value: <0.0001)
higher than the OR in the IDU treatment group. Since
the result based on HK was statistically significant at the
5% level, similar analyses were then sequentially per-
formed for the two ulcer sub-types: dendritic ulcer and
geographic ulcer and the results for both sub-types were
statistically significant at the 2.5% level (for dendritic
ulcer, OR 4.22 (95% CI: 2.14, 8.32; p <0.0001); and for
geographic ulcer, OR 5.31 (95% CI: 1.09, 25.93; p =
0.0244). Results from CMH method were also presented
in forest plots in Figure 3 Primary Meta Analysis Result
with CMH Method for Herpetic Keratitis.
No obvious publication bias was observed based on a
funnel plot (not shown).
Homogeneity was evaluated across all studies included
in the meta-analysis for HK, as well as across all studies
included in the meta-analyses for each of the two ulcer
sub-types: dendritic ulcer and geographic ulcer.
The BDT test for the homogeneity of the odds ratios
did result in significant p-values for the HK (overall)
studies (p = 0.0072), as well as the dendritic ulcer sub-
Table 4 Summary of meta-analysis results on healing of herpetic keratitis at day 7 for acyclovir versus idoxuridine with
CMH method
Group # of Articles
included
Total number of Subjects CMH Test for comparing ACV over IDU BDT test for homogeneity
of odds ratio






Herpetic keratitis 7 214 218 44.54, < 0.0001 3.95 (2.60, 6.00) 17.65 (6), 0.0072
Dendritic ulcers 4 94 91 21.04, < 0.0001 4.22 (2.14, 8.32) 20.71 (3), 0.0001
Geographic ulcers 3 13 22 5.06, 0.0244 5.31 (1.09, 25.93) 4.00 (2), 0.1350
Sensitivity Analysis
(without data from [22])
Herpetic keratitis 6 184 189 22.82, < 0.0001 2.96 (1.89, 4.66) 2.69 (5), 0.7481
Dendritic ulcers 3 64 62 1.24, 0.2657 1.62 (0.69, 3.81) 3.10 (2), 0.2127
*d.f.: degrees of freedom.
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geographic ulcer subtype (p = 0.1357). Collum [22] was
deemed a potential outlier based on larger efficacy effect
in favor of ACV (Figure 3).
For both the analysis of HK and the dendritic ulcer
subtype, a jack-knife analysis was done, where each
study was removed in turn and the analysis was re-
performed. The results from the BDT test for both the
HK group and the dendritic ulcer subtype lost signifi-
cance when Collum [22] was removed (0.7481 for HK
and 0.2127 for dendritic ulcer) while they remained
significant when any of the other studies were re-
moved. This finding suggests that Collum [22] was the
driver behind the statistically significant BDT test for
homogeneity.Table 5 Results of day 7 healing rate estimation for ACV and
Group # of Articles
included
Total number of Subjects
ACV IDU
Herpetic keratitis 7 214 218
Dendritic ulcers 4 94 91
Geographic ulcers 3 13 22
Sensitivity Analysis
(without data from [22])
Herpetic keratitis 6 184 189
Dendritic ulcers 3 64 62The jack-knifed results for the CMH statistic remained
significant and consistent with the original analysis in all
cases except for one. The result from the jack-knife that
lost statistical significance was the analysis on dendritic
ulcers with Collum removed (common odds ratio: 1.62;
95% CI: 0.69, 3.81; p = 0.2657), although the direction
was consistent and still in favor of acyclovir.
Of note, the HK reanalysis without Collum remained
highly significant (common OR: 2.96; 95% CI: 1.89, 4.66;
p-value: <0.0001) and was consistent with the analysis
with all data for the HK ulcers. This shows the robust-
ness of the conclusion that ACV provided improved 7
day healing rates for HK.
In Collum, the healing rates observed from the ACV




Odds 3.70 (2.02, 6.78) 0.89 (0.51, 1.55)
Log Odds 1.31 (0.70, 1.91) −0.12 (−0.68, 0.44)
Healing Rate 0.79 (0.67, 0.87) 0.47 (0.34, 0.61)
Odds 6.63 (1.43, 30.71) 1.26 (0.32, 4.98)
Log Odds 1.89 (0.36, 3.42) 0.23 (−1.15, 1.60)
Healing Rate 0.87 (0.59, 0.97) 0.56 (0.24, 0.83)
Odds 1.17 (0.11, 12.78) 0.22 (0.02, 2.40)
Log Odds 0.15 (−2.24, 2.55) −1.50 (−3.88, 0.87)
Healing Rate 0.54 (0.10, 0.93) 0.18 (0.02, 0.71)
Odds 3.12 (1.55, 6.30) 1.06 (0.55, 2.05)
Log Odds 1.14 (0.44, 1.84) 0.06 (−0.61, 0.72)
Healing Rate 0.76 (0.61, 0.86) 0.51 (0.35, 0.67)
Odds 4.08 (0.43, 38.79) 2.50 (0.29, 21.88)
Log Odds 1.41 (−0.84, 3.66) 0.92 (-1.25, 3.09)
Healing Rate 0.80 (0.30, 0.97) 0.71 (0.22, 0.96)
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given the efficacy outcomes for dendritic ulcers reported
in the literature [28,30]. Day 7 healing rates for ACV
treated dendritic ulcers reached up to 27/28, or 96%
[31]. Day 7 healing rates for IDU treated dendritic ulcers
healing rates were as low as 4/20 or 20% [32].
The Collum [22], study was a randomized, double-
blind trial, which met the inclusion criteria for the meta-
analysis plan and provided day 7 healing rates that were
consistent with those in the available literature. There-
fore it is not excluded from the primary comparison of
interest.
The estimates of treatment effects of ACV and of IDU
from the NLME model for different ulcer types are pre-
sented in Table 5.
It is also helpful to look at the summary of healing
rates for ACV and IDU for HK, dendritic and geographic
ulcers at Day 7 using traditional descriptive statistics
(Table 2). Summary data showed ACV healed 167/214
cases of HK (78%, 95% CI 72-84%) at Day 7 while IDU
healed 103/218 cases (47%, 95% CI 41%-54%) by Day 7.
For dendritic ulcers, ACV was effective in 80/94 cases
(85%, 95% CI 78-92%) while IDU was successful in 50/
91 cases (55%, 95% CI 45-65%). In the setting of geo-
graphic ulcers, there was overlap of the 95% CI between
the treatment arms, but numerical superiority for AVC
(7/13, 54%, 95% CI 27-81%) compared to IDU (4/22,
18%, 95% CI 2-34%). Furthermore, these 7 controlled
studies used in the meta-analysis of primary efficacy in
herpetic keratitis were also reviewed for inclusion of
comparative mean time-to-healing data. Mean time to
healing was reported in five of the seven studies (Colin
[21], Collum [22], Hamard [27], Kitano [24], McCulley
[26]). The mean time to healing for ACV treated eyes
ranged from 4.4 days (Collum [22], Hamard [27]) to 7.5
days (Colin [21]) in 167 patients compared with 5.1 days
(Hamard [27]) to 9.2 days (Collum [22]) in the IDU
treatment groups totaling 168 patients. All 5 papers
showed superiority for acyclovir ophthalmic ointment
compared to IDU. The mean time to healing was statis-
tically significantly shorter in 3 of these 5 reports (Colin
[21], Collum [22], Kitano [24]), and numerically shorter
in the other two (Hamard [27] and McCulley [26]). One
study (Klauber [25]) reported that mean time to healing
was shorter for ACV treated eyes, but the means were
not reported directly.
Ten day healing rates for ACV treated eyes was com-
pared to IDU treated eyes as a post hoc analysis. All
sources, with the exception of Kitano [24] had sufficient
information to derive 10 day rates. Based on the result
from the meta-analysis with the CMH method, in sub-
jects with HK, the odds ratio (OR) of healing at Day 10
in the ACV treatment group is 2.99 times (95% CI: 1.68,
5.30; p-value: <0.0001) higher than the OR in the IDUtreatment group. Since the result based on HK was sta-
tistically significant at the 5% level, similar analyses were
then sequentially performed for the two ulcer sub-types:
dendritic ulcer and geographic ulcer. The results for the
dendritic sub-types was statistically significant at the
2.5% level (for dendritic ulcer, OR 2.40 (95% CI: 1.06,
5.43; p =0.0237); and for geographic ulcer, OR 2.93 (95%
CI: 0.71 12.15; p = 0.1129)).Discussion
The meta-analysis addressed the objective of comparing
efficacy of ACV 3% ophthalmic ointment to IDU in
healing HK on Day 7 of treatment. There were seven
studies of subjects with HK included in the meta-
analysis. From all cases of HK (N = 432) included in the
meta-analysis, 185 cases were identified as dendritic ul-
cers and 35 cases were identified as geographic ulcers.
There is not sufficient information to classify the
remaining cases as specific ulcer sub-type. ACV 3% oph-
thalmic ointment had a statistically higher healing rate
than IDU in terms of OR (common OR of ACV versus
IDU: 3.95; 95% CI: 2.60, 6.00; p < 0.0001). On average
the day 7 healing rate was 79% (95%CI: 67%, 87%) for
ACV and 47% (95%CI: 34%, 61%) for IDU. Analysis
results also demonstrated the statistically significant su-
periority of ACV over IDU in both ulcer sub-
types—dendritic ulcers (common OR of ACV versus
IDU: 4.22; 95% CI: 2.14, 8.32; p <0.0001) and geographic
ulcers (common OR of ACV versus IDU: 5.31; 95% CI:
1.09, 25.93; p = 0.0244). Regarding dendritic ulcers, on
average, the day 7 healing rate was 87% (95% CI: 59%,
97%) for ACV and 56% (95% CI: 24%, 83%) for IDU. For
geographic ulcers, the average day 7 healing rate was
54% (95% CI: 10%, 93%) for ACV and 18% (95% CI: 2%,
71%) for IDU. A post hoc analysis of day 10 healing rates
showed that the advantage of ACV over IDU remains in
HK and the dendritic ulcer subtype remains statistical
significant, but the odds ratios are somewhat attenuated.
An attenuation of the odds ratio for healing at ten days
is not unanticipated as additional time allows for greater
assistance from the host’s immune system.
No obvious publication bias was observed based on a
funnel plot, however publication bias is still a potential
in meta analyses. Outlier analysis did not change the in-
ference of the primary analysis for HK. However, limita-
tions include the modest number of total subjects, and
the age of the studies included. Further, only McCulley
[26] reported planned evaluation on day 7. For subjects
without a day 7 evaluation, healing prior to day 7 was
deemed a success, and healing after day 7 was deemed a
failure.
The safety profile for ACV ophthalmic ointment was
generally favorable. No serious AEs or deaths were
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IDU were occasional transient stinging and superficial
punctate epitheliopathy. These AE’s were not serious
and did not lead to discontinuation of study drug.-ACV
and IDU were generally well tolerated in the studies
reviewed. IDU is superior over placebo in the manage-
ment of HK. [6-10] The use of antiviral agents has re-
duced the frequency of poor visual outcomes in HK
[11]. IDU, however, was the first antiviral agent available
to physicians, and ACV was approved approximately
twenty years later. This meta-analysis shows that ACV
has superior outcomes compared to IDU in HK. Anti-
viral therapy is generally more effective in treating epi-
thelial HK than stromal keratitis, which also requires
anti-inflammatory therapy [4,5].Conclusions
In conclusion, ACV 3% ophthalmic ointment showed
superiority over IDU in the management of HK. Al-
though both medications were well tolerated and have a
favorable safety profile, ACV was significantly more effi-
cacious than IDU in HK generally as well as in the sub-
types of the disease including dendritic and geographic
ulcers. These findings support the efficacy of ACV 3%
ophthalmic ointment in HK and further demonstrate the
value of this topical therapeutic in HK.
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